Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Common Stock Repurchased

Cash spent buying back the company's own shares.

Teleflex IncorporatedNYSE: TFX

Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026

Common stock repurchased growth accelerates

Q2 FY2026 common stock repurchased of $245.37M (cash outflow) rose 12855.3% year over year, ahead of the -50.2% change in trailing-twelve-month common stock repurchased. Sequentially, it rose 5203.1% from the prior quarter. Over 3 fiscal years it compounded at +311.4% a year.

Context

  • Common stock repurchased amounted to 15.1% of revenue in FY2025, up 8.5 pp from a year earlier.
  • Common stock repurchased increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +12855.3% holds above the trailing-twelve-month pace of -50.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$245.37M+5203.1% QoQ
Last fiscal yearDec 2025
-$300M+50.0% YoY
LTMJun 2026
-$250.05M-50.2% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12855.3%——
1 year+50.0%——
3-year CAGR+311.4%——
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
(300M) USD
Year-over-year change
-50.0%

Common Stock Repurchased vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -50.2% is the lowest of 4, against a peer median of +350.0%.
  • Common stock repurchased amounts to 9.6% of revenue for TFX, versus a peer median of 0.0%.
TFX Competitors
Common Stock Repurchased for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TFXTeleflex IncorporatedLTM Jun 2026$250.05M USD-50.2%+311.4%9.6%
TGTXTG Therapeutics, Inc.LTM Sep 2026$199.99M USD+104.4%—22.3%
ALKSAlkermes plcLTM Sep 2026$31.03M USD+3103100.0%+19.5%1.8%
BLCOBausch + Lomb CorporationLTM Jun 2026$27M USD+350.0%—0.5%
KRYSKrystal Biotech, Inc.LTM Jun 2026$17.07M USD——3.9%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$0 USD——0.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$0 USD——0.0%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$0 USD——0.0%
STVNStevanato Group S.p.A.LTM Jun 2026€0 EUR——0.0%
CRSPCRISPR Therapeutics AGLTM Sep 2026$0 USD——0.0%
Peer median (excluding TFX) —+350.0%+19.5%0.0%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income485.37M363.14M356.33M69.68M58.53M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
Deferred Income Tax(110.24M)(13.01M)(13.05M)0(100.97M)
Stock-Based Compensation22.94M27.22M31.47M31.35M0
Change in Working Capital127.35M(239.96M)(111.77M)(1.82M)(81.09M)
Accounts Receivables(600K)(38.46M)(15.76M)(27.95M)(85.53M)
Inventory(11.14M)(110.69M)(41.07M)1.72M84.04M
Accounts Payables94.02M(24.79M)(31.26M)9.67M(8.28M)
Other Working Capital45.06M(66.03M)(23.68M)14.74M(71.31M)
Other Non-Cash Items(111.36M)(25.84M)5.55M261.94M286.46M
Operating Cash Flow651.42M342.14M510.64M635.74M340.68M
Capital Expenditures(71.62M)(79.19M)(91.44M)(126.43M)(95.24M)
Acquisitions (Net)220.32M(186M)(588.92M)(120K)(825.15M)
Purchases of Investments(18.42M)(22.3M)(11.3M)(7.3M)(5M)
Sales of Investments7.3M7.3M7.3M7.3M0
Other Investing Activities19.15M22.24M63.13M27.2M76.19M
Investing Cash Flow156.74M(257.94M)(621.23M)(99.36M)(849.19M)
Debt Repayment(634.5M)(145.45M)101.25M(161.5M)982.04M
Common Stock Issued11.1M4.31M000
Common Stock Repurchased0(4.31M)0(200M)(300M)
Dividends Paid(63.65M)(63.79M)(63.9M)(63.54M)(60.27M)
Other Financing Activities(28.77M)(8.27M)1.19M3.12M(10.23M)
Financing Cash Flow(715.82M)(217.51M)38.54M(421.93M)611.54M
Effect of Forex Changes(23.13M)(19.74M)2.86M(9.65M)(29.35M)
Net Change in Cash69.2M(153.05M)(69.19M)104.8M73.68M
Free Cash Flow579.8M262.95M419.2M509.31M245.44M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.